Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
Technology Ventures News
Staying alive: Can an experimental OMRF drug stop Mike Schuster’s brain cancer?
As Mike Schuster nears the three-year anniversary of his diagnosis with glioblastoma, he’s already doubled the life expectancy for patients with the deadly cancer.
OMRF enters into a license agreement with Shanghai RAAS Blood Products
OMRF has entered a license agreement with Shanghai RAAS Blood Products for development of novel hemophilia treatment.
Predicting lupus flares?
Lead investor i2E, along with Chicago-based OCA Ventures and Rochester-based Mayo Clinic Ventures, funded in late November the first round of investment to assist Progentec Diagnostics in moving its predictive technology for the onset of lupus flares closer to commercialization.
New tools for predicting lupus flares now one step closer to market
Progentec Diagnostics, Inc. has completed first round financing of $1.25 million.
OMRF collaborates with GSK to develop novel treatments for severe inflammatory diseases
This collaboration is part of GSK’s “Discovery Partnerships with Academia” (DPAc) efforts.
